نتایج جستجو برای: tissue plasminogen activator

تعداد نتایج: 954526  

Journal: :Stroke 2009
David J Gladstone Lance H Rodan Demetrios J Sahlas Liesly Lee Brian J Murray Jon E Ween James R Perry Jordan Chenkin Laurie J Morrison Shann Beck Sandra E Black

BACKGROUND AND PURPOSE Intravenous tissue plasminogen activator for ischemic stroke is approved for eligible patients who can be treated within a 3-hour window, but treatment rates remain disappointingly low, often <5%. To improve rapid access to stroke thrombolysis in Toronto, Canada, a citywide prehospital acute stroke activation protocol was implemented by the provincial government to transp...

Journal: :Annals of the rheumatic diseases 1996
A L Herrick K Illingworth A Blann C R Hay S Hollis M I Jayson

OBJECTIVE To determine whether measurement of different markers of endothelial damage, activation of coagulation, and platelet activation might differentiate between patients with primary Raynaud's phenomenon (PRP), limited cutaneous and diffuse systemic sclerosis (lcSSc and dSSc), and healthy control subjects. METHODS Under carefully controlled conditions, fasting blood was drawn from 19 hea...

Journal: :Stroke 2000
L Johansson J H Jansson K Boman T K Nilsson B Stegmayr G Hallmans

UNLABELLED BACKGROUND NAD PURPOSE: Abnormalities in the fibrinolytic system have been associated with an increased risk for stroke in a few studies. This study was designed to test whether plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and tPA/PAI-1 complex could predict a first-ever stroke. METHODS The study was an incident case-control study ...

2013
Lourdes Acosta Abdelkrim Hmadcha Natalia Escacena Inmaculada Pérez-Camacho Antonio de la Cuesta Rafael Ruiz-Salmeron Benoit R. Gauthier Bernat Soria

Stem cells have been successfully used for the treatment of critical limb ischemia (CLI). We conducted a clinical trial to determine the feasibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of CLI. Unexpectedly, two diabetic patients developed peripheral microthrombosis. This adverse effect, which contrasts with the reported antithrombotic propert...

Journal: :The Journal of clinical investigation 1968
C S Kucinski A P Fletcher S Sherry

Antiserum against purified human urokinase was produced by immunization of Hartley strain guinea pigs. The antiserum was capable of neutralizing the plasminogen activator activity of the antigen and of native urokinase in human urine. The antiserum did not inhibit plasminogen activators of bacterial origin, i.e., streptokinase and staphylokinase; neither did it inhibit urokinase from nonprimate...

2007
Benjamin D. Sachs George S. Baillie Julianne R. McCall Melissa A. Passino Christian Schachtrup Derek A. Wallace Allan J. Dunlop Kirsty F. MacKenzie Enno Klussmann Martin J. Lynch Shoana L. Sikorski Tal Nuriel Igor Tsigelny Jin Zhang Miles D. Houslay Moses V. Chao Katerina Akassoglou

Tissue scarring, characterized by cell activation, excessive deposition of ECM, and extravascular fi brin deposition, is considered a limiting factor for tissue repair. Fibrin, the major substrate of the serine protease plasmin, is a provisional matrix deposited after vascular injury (Bugge et al., 1996). The two plasminogen activators (PAs), namely tissue plasminogen activator (tPA) and urokin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید